Evidence map›Paper›PMID 17166221›Full record

Trial reportBJOG : an international journal of obstetrics and gynaecology2007

The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for children at 18 months.

Magpie Trial Follow-Up Study Collaborative Group

Open access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BJOG : an international journal of obstetrics and gynaecology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 12 pooled it
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 12 syntheses or guidelines pooled it, 164 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pre-eclampsia, eclampsia, and hypertension.BMJ clinical evidence · 2011
    Pooled it
  9. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia.The Cochrane database of systematic reviews · 2010
    Pooled it
  10. Pooled it
  11. Pooled it
  12. Pre-eclampsia, eclampsia, and hypertension.BMJ clinical evidence · 2008
    Pooled it
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Therapeutic potential of extracellular vesicles for treating human pregnancy disorders.Extracellular vesicles and circulating nucleic acids · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Magpie Trial Follow-Up Study Collaborative Grouplelia.duley@ndm.ox.ac.uk

Funding

Medical Research Council G116/98
6 · The paper itself

Abstract

objectiveTo assess the long-term effects of in utero exposure to magnesium sulphate for children whose mothers had pre-eclampsia.

designAssessment at 18 months of age for children whose mothers were recruited to the Magpie Trial (recruitment 1998-2001 ISRCTN 86938761), which compared magnesium sulphate with placebo.

settingFollow-up of children born at 125 centres in 19 countries across five continents. POPULATION: A total of 6922 children were born to women randomised before delivery at follow-up centres. Of these, 2271 were not included for logistic reasons and 168 were excluded (101 at a centre where <20% were contacted, 40 whose death or disability was due to a problem at conception or embryogenesis and 27 whose parent/s opted out). Therefore, 4483 children were included in follow-up, of whom 3283 (73%) were contacted.

methodsAssessment by questionnaire, with interview and neurodevelopmental testing of selected children.

main outcome measuresDeath or neurosensory disability at age of 18 months.

resultsOf those allocated magnesium sulphate, 245/1635 (15.0%) were dead or had neurosensory disability at 18 months compared with 233/1648 (14.1%) allocated placebo (relative risk [RR] 1.06, 95% CI 0.90-1.25), and of survivors, 19/1409 (1.3%) had neurosensory disability at 18 months compared with 27/1442 (1.9%) (RR 0.72, 95% CI 0.40-1.29). There were no substantial differences in causes of death or in the risk of individual impairments or disabilities.

conclusionsThe lower risk of eclampsia following prophylaxis with magnesium sulphate was not associated with a clear difference in the risk of death or disability for children at 18 months.

Indexed as

AnticonvulsantsChildren with DisabilitiesDisability EvaluationFemaleHumansInfantMagnesium SulfateNervous System DiseasesPre-EclampsiaPregnancyPregnancy OutcomePrenatal Exposure Delayed EffectsSensation DisordersAnticonvulsantsMagnesium Sulfate

Identifiers

PMID17166221
PMCPMC2063969
OpenAlexW312649256

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.